Le Fourgon specializes in the home delivery of a variety of drinks, including milk, water, beer, wine, fruit juice, and sodas. The company operates a sustainable delivery model by providing drinks in recyclable bins, which are collected during the next delivery, ensuring that customers receive their orders quickly and conveniently. This service includes free daytime delivery, allowing consumers to enjoy their preferred beverages without the hassle of shopping. Le Fourgon's approach not only meets consumer demand for convenience but also emphasizes ecological sustainability through its use of recyclable packaging.
TrustUp is a platform that connects homeowners with verified home improvement contractors. It operates as a marketplace for construction and renovation services, helping users find reliable professionals for various home projects. TrustUp focuses on ensuring quality by providing a guarantee for the work completed, enabling customers to access consistent and effective professional services. By streamlining the process of hiring home service providers, TrustUp aims to enhance the overall experience for homeowners seeking trustworthy assistance with their home improvement needs.
Veoware Limited, based in Guildford, United Kingdom, specializes in providing satellite imagery services through its innovative data platform and analytics. Established in 2016, the company is developing a space-based system that allows customers to access satellite imagery at any time and from any location on Earth. Veoware aims to simplify and enhance the usability of satellite systems, making them accessible to a diverse range of clients. By improving the efficiency and responsiveness of satellite operations, Veoware enables users to industrialize the space sector, ensuring that hardware, software, and data are readily available for various applications.
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance over treatment.
Get Your Way specializes in the development of innovative connected glasses tailored for assisted reality applications in industrial settings. The company focuses on a frugal innovation approach, which effectively reduces barriers to adoption by addressing cost, comfort, and user interest. Its smart glasses feature low-power augmented reality capabilities and a removable battery, alleviating concerns about power depletion. Additionally, Get Your Way develops accompanying software that facilitates the creation and management of workflow procedures, enabling businesses to streamline operations and transition towards Industry 4.0. By targeting new customer segments and applications, the company aims to democratize access to augmented reality technology within the industry.
Hedera-22 is engaged in the identification of natural products and the development of a DNA-based synthesis platform aimed at enhancing the production of new molecules through targeted genetic modifications. The company utilizes in-house bio-informatic prediction technologies to provide comprehensive services related to the computational analysis of biological data. By integrating strategies from environmental microbiology and bioinformatics, Hedera-22 supports the healthcare sector with an advanced predictive bioinformatics platform, facilitating improved research and development in molecular biology.
SamanTree Medical is a swiss innovative medical device company providing a breakthrough imaging solution with the potential to improve patient care and cancer surgery outcome. Based on confocal microscopy, SamanTree Medical’s solution brings accurate and full margin control by the surgeon, in the operating room.
Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
Novobiom specializes in bioremediation services that focus on treating contaminated soil through innovative biological methods. The company employs mycoremediation technology, utilizing mushrooms to effectively address persistent pollutants in the environment. This approach offers tailored solutions for soil pollution, enabling industries to remediate contaminated sites while promoting sustainability. In addition to its remediation services, Novobiom provides consultation on waste management and sustainability, guiding clients toward achieving their strategic environmental goals through biomimetic principles.
Exo Biologics is a biotechnology company focused on the development of biopharmaceuticals utilizing extracellular vesicles, specifically exosomes. The company aims to create novel therapeutic candidates for conditions such as dysplasia and Crohn's disease. By leveraging the natural properties of exosomes, Exo Biologics facilitates intracellular communication among cells, allowing for the transfer of proteins, lipids, and genetic material. This approach enables effective signaling to recipient cells through various receptors. The company's commitment to large-scale production ensures that its therapeutic candidates are not only cost-effective but also highly consistent, ultimately providing affordable and accessible treatment options for patients with significant unmet medical needs.
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.
Raw Stadia is a sports technology company focused on enhancing player interactions with playing surfaces. It develops performance analytics technology aimed at managing stadium and training pitches to optimize player performance. By providing data that ensures safer playing surfaces, Raw Stadia helps reduce player injuries, which can lead to improved athletic performance and increased success for teams. This approach not only benefits players but also contributes to greater fan satisfaction and healthier clubs overall.
Samabriva is a biotechnology company which has developed a disruptive platform (the “RHIZOBRIVA™” platform) from plant material enabling the production of biomolecules suitable for the pharmaceutical industry, as well as the cosmetics, agrochemicals and food industries. More recently, Samabriva has built an independent business unit (the “NANOBRIVA™” platform) focused on the development of orphan drugs for the treatment of lysosomal storage disorders (« LSD »). In this business unit, the company develops proprietary lysosomal enzymes with novel and enhanced bioavailability features, taking advantage of an innovative technology compatible with all production systems (mammalian cell cultures, bacteria, etc …).
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Ampacimon SA specializes in manufacturing dynamic line rating systems for transmission and distribution system operators globally. Founded in 2010 and headquartered in Grace-Hollogne, Belgium, with an additional office in Cumming, Georgia, the company offers a range of innovative products designed to enhance grid infrastructure. These include ADR View, a modeling tool that utilizes historical weather data; ADR Sense, a self-powered vibration sensor; and ADR Operate, a real-time data-acquisition engine that retrieves crucial operational parameters. Additionally, Ampacimon provides ADR Trend and ADR Horizon for short- and medium-term ampacity forecasting. These solutions enable grid operators to anticipate congestion issues and implement cost-effective reconfiguration strategies, thereby addressing challenges related to aging infrastructure, congestion, and the integration of renewable energy sources.
RISORCE fills a need in Belgium for local solutions for processing tire waste while remaining dedicated to a circular economy strategy. We provide a regionally-based, technologically and environmentally sound solution.
Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.
Axithra is a company that specializes in therapeutic medication monitoring, specifically focusing on beta-lactam antibiotics. The business has developed a platform that enables rapid and accurate measurement of drug concentrations in the bloodstream, which is essential for personalized treatment in intensive care settings. By utilizing proprietary optical and photonics technology, Axithra's application allows healthcare providers to tailor antibiotic treatments to the individual needs of patients. This innovation aims to enhance patient care by ensuring that drug levels are monitored effectively, facilitating prompt adjustments to optimize therapeutic outcomes.
Purecontrol is a developer of industrial automation systems that leverages artificial intelligence to facilitate continuous improvement in complex installations. The company's platform employs AI algorithms to analyze equipment operations, predict maintenance needs, and optimize performance. By enhancing process reliability and operational efficiency, Purecontrol helps companies achieve lower energy costs and reduce their carbon footprint. Its innovative solutions aim to improve overall industrial performance while promoting sustainability.
Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
Myocene is a Liège-based sports technology company which creates unique and innovative devices for measuring muscle fatigue and performance.
IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.
DeuterOncology is a preclinical-stage biotech company focusing on the development of a first-in-class dual MET and RAS pathway inhibitor for targeted cancer therapies.
Algama is a food-tech company focused on developing sustainable food solutions through the use of microalgae. Established in 2013, Algama aims to address global food challenges by harnessing the nutritional and functional properties of algae to produce plant-based alternatives to animal products, such as eggs and meat. Its innovative platform also creates emulsifiers that help food manufacturers replicate the taste and texture of traditional animal-based foods. With a vision to feed 10 billion people by 2050 while preserving the planet, Algama is dedicated to making microalgae a key resource for the future of food. The company is recognized as a world leader in this sector and is supported by a range of prominent impact investors. Algama emphasizes the importance of making its products accessible, affordable, and appealing to consumers, while continually seeking talent and innovation to advance its mission.
MyCellHub is a pre-startup from KULeuven focused on transforming cell production processes within the biotherapeutics industry. The company has developed a regulatory-compliant software-as-a-service (SaaS) platform that streamlines data management and analytics for laboratory and cleanroom workflows. This platform enables users to capture real-time data from multiple sources, integrating seamlessly with existing enterprise resource planning (ERP) systems. By providing actionable insights through cell culture-specific process analytics, MyCellHub enhances manufacturing efficiency while ensuring regulatory compliance through features like real-time audit trails and automated batch records. The company's solutions aim to optimize data reporting and management, ultimately improving the overall productivity of manufacturing processes in the sector.
Intressa Vascular focuses on developing innovative solutions for cardiovascular conditions, particularly addressing aortic dissection. The company utilizes a proprietary braiding technology platform to create multilayer stents designed for next-generation endovascular treatments. These products assist physicians in effectively managing the serious impacts of aortic dissections, ultimately aiming to enhance patient outcomes while minimizing the risk of ischemic complications. By fostering a collaborative and constructive approach, Intressa Vascular is committed to advancing patient care through high-quality medical products.
Graftys is an early-stage company based in Aix-en-Provence, France, specializing in advanced bone biologics. The company develops synthetic bone biomaterials specifically designed for reconstructive orthopedic surgery. Graftys offers a range of innovative and fully injectable calcium phosphate bone graft substitutes that are tailored for various clinical applications. By focusing on safety and quality, Graftys aims to provide effective solutions for patients undergoing bone reconstructive and trauma surgery.
Maana Electric focuses on developing innovative technologies for sustainable energy, particularly in the solar sector. The company aims to revolutionize solar panel manufacturing through in-situ resource utilization (ISRU) technologies, which facilitate the production of solar panels both on Earth and in space. By applying a system engineering approach, Maana Electric addresses significant challenges across the solar supply chain, emphasizing green manufacturing processes for solar panels, cells, and silicon production. Their mission extends beyond Earth, aspiring to establish themselves as the first solar system utility company and contributing to the advancement of humanity towards becoming a space-faring civilization. Through their efforts, they seek to combat global warming and ensure a sustainable future for generations to come.
Eclo grows substrates for exotic mushroom growers.
Aerospacelab SA, founded in 2017 and headquartered in Mont-Saint-Guibert, Belgium, specializes in the development and manufacturing of small satellites equipped with advanced sensors. The company focuses on addressing complex challenges through innovative solutions, including the use of artificial intelligence and machine learning to automate various tasks. Aerospacelab's technology enables the collection of high-resolution optical data and provides a platform that facilitates the analysis of large datasets. This capability allows customers to effectively survey and monitor diverse applications, optimizing the transformation of the information gathered.
IONNYK is the first art photography platform that elevates the art experience while allowing for imagination and originality.
VistaCare is a French company specializing in the development, manufacturing, and distribution of medical devices designed for the treatment of acute and chronic wounds. The company focuses on innovative, non-contact treatment methods that operate in a controlled environment. Their technology addresses critical aspects of wound care, including the reduction of nosocomial risks, visual monitoring of wound progression, and tailored medical protocols based on the specific type and stage of each wound. By enhancing the quality of life for patients and streamlining the care process for caregivers, VistaCare aims to significantly reduce treatment times and hospital stays, offering a more effective solution for complex wounds that are challenging to manage with conventional therapies.
EyeD Pharma SA is a pharmaceutical company based in Liège, Belgium, specializing in the development and commercialization of innovative drug products for ophthalmology. The company focuses primarily on the treatment of glaucoma, a condition traditionally managed through daily eye drop administration. EyeD Pharma aims to enhance the quality of life for patients by creating therapies that reduce side effects associated with existing treatments. In collaboration with ophthalmologists, the company offers new treatment options and surgical products, helping to improve clinical practices and provide therapeutic assistance that is currently lacking in the market.
PDC*line Pharma is a French-Belgium clinical-stage biotech company that develops a new class of active immunotherapies for cancer based on an allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line) loaded with cancer antigens. PDC*line Pharma originated from a flagship R&D program of the French Blood Bank (EFS, Etablissement Français du Sang) where PDC*line, a proprietary Plasmacytoid Dendritic Cell line (PDC) was developed from a patient with a PDC leukemia. Laurent LEVY President France & COO, and Joel PLUMAS, CSO founded the company in April 2014 in Grenoble and took the project to the clinical development stage with non-dilutive funding. Eric Halioua joined the team in February 2016, and became President and CEO in July 2016.
Amyl Therapeutics is a preclinical stage biotechnology company. Amyl Therapeutics uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-β (Aβ), Tau, and α-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases.
Respiratory diseases affect 270 million children worldwide every year and put a $120B direct cost burden on the healthcare systems. Despite being a priority for WHO and international societies, respiration diseases remain largely under-diagnosed and poorly managed. Gabi SmartCare is a med-tech start-up developing predictive at-home monitoring solutions for early diagnostics and daily management of chronic respiratory diseases.
ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.
GeneQuine Biotherapeutics designs and develops gene therapies for its clients. The therapies developed by the company aim to treat osteoarthritis. Its product portfolio consists of GQ-201, GQ-202, and GQ-203. GeneQuine Biotherapeutics was founded in 2011 by Stanislav Plutizki and Kilian Guse.
ABSCINT engages in the development of radiolabelled single-domain antibodies for whole-body molecular imaging applications. Molecular imaging is used for the diagnosis of disease, the molecular characterization of a disease, monitoring treatment response, and the detection of disease recurrence.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Ampacimon SA specializes in manufacturing dynamic line rating systems for transmission and distribution system operators globally. Founded in 2010 and headquartered in Grace-Hollogne, Belgium, with an additional office in Cumming, Georgia, the company offers a range of innovative products designed to enhance grid infrastructure. These include ADR View, a modeling tool that utilizes historical weather data; ADR Sense, a self-powered vibration sensor; and ADR Operate, a real-time data-acquisition engine that retrieves crucial operational parameters. Additionally, Ampacimon provides ADR Trend and ADR Horizon for short- and medium-term ampacity forecasting. These solutions enable grid operators to anticipate congestion issues and implement cost-effective reconfiguration strategies, thereby addressing challenges related to aging infrastructure, congestion, and the integration of renewable energy sources.
ExeVir Bio BV, founded in 2020 and based in Zwijnaarde, Belgium, specializes in developing single-domain antibody-based therapies aimed at combating viral infections. The company leverages a llama-derived antibody technology platform to create robust antiviral treatments that offer broad protection against coronaviruses. Notably, it is developing VHH72-FC, an antibody that targets a highly conserved region on the spikes of SARS-CoV-2, crucial for the virus's entry into human cells. ExeVir Bio's rapid response platform for antivirals allows for an agile approach to emerging health threats, enabling the swift generation of drug candidates. The therapeutics produced through this innovative technology are designed to be stable, cost-effective, and accessible on a global scale.
e-peas SA is a Belgian company that specializes in designing and manufacturing electronic systems that enable energy autonomy for Internet of Things (IoT) applications. Founded in 2014 and based in Mont-Saint-Guibert, the company develops energy harvesting solutions that allow IoT devices to draw power from their environment, including sources such as solar, thermal, vibration, and radiofrequency. e-peas produces energy harvesting power management integrated circuits (PMICs) and low-power microcontrollers that enhance the performance and longevity of batteries in connected devices. By facilitating the efficient use of ambient energy, e-peas aims to reduce the need for frequent battery replacements across various sectors, including home automation, healthcare, and agriculture. The company's innovations contribute to making IoT devices smarter and more energy-efficient, ultimately striving for a future where devices can operate indefinitely without traditional power sources.
Bloomlife is a women's health company focused on addressing critical challenges in maternal health through an innovative remote care platform. By integrating connected devices with cloud-based data analytics, Bloomlife enhances access to care and empowers expectant mothers while providing clinicians with essential information to better screen and manage pregnancy complications. The company's prenatal wearable technology is designed to assess fetal health, enabling the identification of potential complications that could lead to serious outcomes such as brain damage or stillbirth. This approach marks a significant departure from traditional methods of managing high-risk pregnancies, which often involve frequent in-person appointments and lengthy referral processes. Bloomlife aims to be a leader in remote maternal care, facilitating timely interventions and support for women, regardless of geographic barriers.
Hyloris Pharmaceuticals SA is a specialty pharmaceutical company based in Liege, Belgium, founded in 2013. The company focuses on reformulating well-known pharmaceuticals to enhance their value within the healthcare system. Hyloris develops proprietary products aimed at addressing unmet medical needs across various areas, including cardiovascular diseases such as atrial fibrillation, congestive heart failure, and coronary heart disease. Its product portfolio includes intravenous ready-to-use formulations, oral liquid formulations, and topical gel and cream products. Hyloris currently offers two early commercial-stage products: Sotalol IV, intended for atrial fibrillation treatment, and Maxigesic IV, a non-opioid analgesic. The company aims to provide significant advantages over existing alternatives for patients, healthcare providers, and other stakeholders.
IVEX is a start-up originating from the University of Leuven, specializing in the development of tools and software designed for the testing and validation of advanced driver assistance systems (ADAS) and autonomous vehicles. The company comprises a diverse team and has established partnerships with global firms, notably Siemens, to enhance its growth in the high-tech sector. IVEX offers a cloud-based suite of testing and validation tools alongside an onboard real-time safety checker, which can function independently or in conjunction with other systems. Its solutions streamline the analysis of extensive driving data, enabling engineers to efficiently identify and categorize driving scenarios, create digital representations for simulation, and assess safety performance while minimizing computational resource usage. By focusing on safety and efficiency, IVEX aims to support the industry's need for reliable and effective validation of automated driving technologies.
Odoo is an open-source platform that offers a comprehensive suite of integrated business applications aimed at managing various company operations. Its tools encompass customer relationship management (CRM), eCommerce, accounting, inventory management, point of sale, and project management, among others. These applications are designed to work cohesively, facilitating seamless workflows across different departments within a business. Odoo enables organizations to automate processes and monitor activities from any device, thus enhancing efficiency and productivity in managing their operations.
MyCellHub is a pre-startup from KULeuven focused on transforming cell production processes within the biotherapeutics industry. The company has developed a regulatory-compliant software-as-a-service (SaaS) platform that streamlines data management and analytics for laboratory and cleanroom workflows. This platform enables users to capture real-time data from multiple sources, integrating seamlessly with existing enterprise resource planning (ERP) systems. By providing actionable insights through cell culture-specific process analytics, MyCellHub enhances manufacturing efficiency while ensuring regulatory compliance through features like real-time audit trails and automated batch records. The company's solutions aim to optimize data reporting and management, ultimately improving the overall productivity of manufacturing processes in the sector.
Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.
Graftys is an early-stage company based in Aix-en-Provence, France, specializing in advanced bone biologics. The company develops synthetic bone biomaterials specifically designed for reconstructive orthopedic surgery. Graftys offers a range of innovative and fully injectable calcium phosphate bone graft substitutes that are tailored for various clinical applications. By focusing on safety and quality, Graftys aims to provide effective solutions for patients undergoing bone reconstructive and trauma surgery.
Phasya specializes in advanced eye tracking technologies that detect drowsiness and measure eye movements through high-speed camera systems integrated into glasses. Their solutions provide automatic, objective, and real-time assessments of ocular parameters, which are crucial for understanding various physiological and cognitive states, including stress, attention, cognitive load, and mind wandering. These technologies find applications across safety, medical diagnostics, and research, with a strong focus on driver monitoring. By measuring ocular parameters, Phasya’s innovations contribute to assessing an individual's ability to perform tasks and make decisions, ultimately enhancing safety and operational performance in various environments.
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Onoff Telecom offers a variety of products for private and business customers that seek to revolutionize communications.
Convert Pharmaceuticals SA, founded in 2017 and based in Saint-Gilles, Belgium, focuses on the development of hypoxia-activated cytotoxic small molecules for cancer treatment. As a clinical phase I-IIa drug development company, Convert Pharmaceuticals is building a proprietary pipeline that targets tumor microenvironment-specific factors to enhance therapeutic outcomes. The company's lead product is a hypoxia-activated prodrug (HAP), designed to overcome the challenges posed by hypoxia, which often leads to resistance against conventional anti-cancer therapies. By integrating proprietary insights into the tumor microenvironment with advanced drug and biomarker development expertise, Convert Pharmaceuticals aims to provide effective and well-tolerated treatment options for cancer patients.
Soundbops is focused on enhancing music education for young children through innovative musical building blocks. These blocks feature colored buttons that produce eight distinct instrument tones, allowing for endless combinations and the creation of chords and songs. By providing an engaging and interactive learning tool, Soundbops aims to foster a love for music in early childhood development. The company is in the process of launching and is seeking advisers and co-founders with expertise in marketing to support its growth.
Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.
Aerosint specializes in innovative 3D printing technology, focusing on a unique selective powder recoating process. This technology utilizes patterning drums to deposit fine powder voxels in a line-by-line manner, creating a powder layer composed of multiple materials ready for sintering. By enabling multimaterial 3D printing, Aerosint allows for the successive sintering of different powders within each layer, facilitating the production of complex parts without generating waste. Their approach to polymer powder bed printing is designed to be cost-effective while maintaining high performance, making it particularly suitable for high-performance polymers. This zero-waste process not only enhances efficiency but also reduces costs for clients seeking advanced 3D printing solutions.
TConcept offers you the perfect brewing appliance, Teh®. This unique device will be launched on the market this year and will be able to provide extraordinary premium tea taste and olfactory sensation by respecting the infusion procedures. The ultimate tea experience. Fully automatic, their appliance provide to the tea an appropriate infusion vessel to enable tea leaves deliver their precious oils and ingredients. In its system, T-Concept has designed and developed a unique brewing apparatus where the internal part of the chamber (called the brewing vessel) is connected to the tea cartridge. Both are tightly sealed. The water is poured in the vessel and (being the cartridge sealed to it) gently flows into the capsule and prevent a thermal shock to raw material. Their brewing appliance has many capacities, including a recognition system by colors which allows him to select the appropriate temperature for each type of tea (each one of them possess her own color). It's also capable of performing an automatic rinsing and a capsule ejection, can display the brewing time, the temperature and the progress percentage for each brewing. And he can do it all with a contemporary design, giving you the feeling of meeting a real tea expert. Their capsules, with their special and transparent packaging, allow you too see the tea, his color and his ingredients and even smell all of his aromas and to make the perfect choice.
Bloomlife is a women's health company focused on addressing critical challenges in maternal health through an innovative remote care platform. By integrating connected devices with cloud-based data analytics, Bloomlife enhances access to care and empowers expectant mothers while providing clinicians with essential information to better screen and manage pregnancy complications. The company's prenatal wearable technology is designed to assess fetal health, enabling the identification of potential complications that could lead to serious outcomes such as brain damage or stillbirth. This approach marks a significant departure from traditional methods of managing high-risk pregnancies, which often involve frequent in-person appointments and lengthy referral processes. Bloomlife aims to be a leader in remote maternal care, facilitating timely interventions and support for women, regardless of geographic barriers.
Preesale is a mobile-based ticket management application designed for event organizers to efficiently manage events and sell tickets. Founded in 2015 and based in Liege, Belgium, Preesale differentiates itself by allowing organizers to access cash flows before their events, enhancing revenue generation and targeting qualified leads. The application integrates seamlessly with Facebook, enabling users to create and sell tickets in under five minutes. Additionally, it provides analytical tools to track sales, facilitates communication with guests through text messages, and offers a smartphone-based ticket scanning feature for event entry. Overall, Preesale aims to improve visibility and accessibility to events, streamlining the ticketing process for both organizers and attendees.
YouScribe is a French community platform established in 2010 that facilitates the sharing and selling of digital publications. Based in Paris, it provides users with a comprehensive online digital library that includes tens of thousands of publications. The platform encourages reading, discussion, and interaction among users, allowing them to build personal libraries and publish their own writings or digital documents for public access. YouScribe's services support the digitalization of written texts, enabling content holders to increase their visibility and reach through various features that enhance the accessibility of their documents across multiple devices.
Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
Aldento is a manufacturer of hand-made pasta made from edible insect flour with the goal of improving both nutritional value and environmental value. The food items produced by the company are prepared with insect flour, integrated grains, and nuts. They provide consumers with a fine dining option that is quick and simple to make, easy to incorporate into daily life, and environmentally friendly, allowing them to switch up their regular meals and use them in place of meat and fish.
Herrmutt Lobby is a collective of musicians, handymen and programmers whose main objective is to develop hardware and software devices.
Student & Go is THE new professional social network for students and employers which aims to help students and fresh graduates thrive in a student job (summer jobs, internships, first jobs) in relation to their studies, while building their professional network. The place to be for students, fresh graduates and for companies : www.studentandgo.com
2-Observe company is active in observational research and validation of innovative concepts in the biotechnology sector and private health care. Founded in 2010, 2-Observe company was born from the concern of its founders of meeting the needs observed in the field by providing effective solutions to improve quality of life. It was built from the experience of its associates from the medical community, the research sector and the industry field of life sciences. Jean-Philippe Hermanne MD, Internist and Head of Department of Oncology in the Centre Hospitalier Régional of Namur (Belgium), with expertise in intensive care and emergency services. Isabelle Joslet, Specialist in Public Health with a long experience as Coordinator of university research programs. Pierre Bothy, Senior Consultant in the medical device industry.
Elysia developed solution dedicated to quality control laboratories for the production of Radio Pharmaceuticals.
XDC S.A. operates as a Pan-European digital cinema service company. It manages operations for the deployment of digital cinema systems in theatres; and prepares and delivers digital content, which is distributed in cinemas, as well as manufactures digital cinema products, including servers, theatre management systems, projections systems, and central libraries. The company's products include CineStore Systems, a suite of digital cinema solutions; The CineStore Solo G3, a hybrid digital cinema server that offer JPEG 2000 and MPEG-2 play-back capabilities; The CineStore Audi, a device, which provides digital to analogue conversion, external analogue audio source inputs, and signal isolation; The CineStore Plaza, a hardware and software suite that enables its users to manage a cinema multiplex from a single point, as well as 3D digital cinema. XDC S.A. also provides digital content lab for the whole production, post-production, and distribution chain, as well as to synchronize various sounds and subtitle versions on the master; key management and archiving; network operations centre, which includes a spare parts logistical strategy centre and a NOC equipment centre; and XDC Entertainment, a content delivery platform to alternative content distributors/providers. The company was founded in 2004 and is based in Liège, Belgium with additional offices in Belgium, Germany, Spain, and France.